Company intelligence / Profile preview

AMIpharm

Ownership: Private
Employees: ~900
Development stage: Commercial

Overview

The Korean branch focuses on innovative phospholipid-derived medications and next-generation injection lipolysis, with recent investment to accelerate commercialization. The Sudanese entity manufactures over 100 pharmaceutical products covering all main cities in Sudan.[1][2][3]

Therapeutic areas: Other
Modalities: Small molecules (general pharmaceuticals)[3]Phospholipid-based therapeutics[1]
Industry: Biotech

Drug pipeline

1 asset

phosphatidylcholine + deoxycholic acid

Commercial

Indications: Localized fat reduction

Beyond the preview

Go deeper on AMIpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMIpharm.

Explore the full profile